

REMARKS

Claims 1-15 are pending in the application. Claims 2 and 4 are objected to. Claims 5-6 and 11-15 are rejected. Claims 5, 6 and 14 are currently cancelled. Claims 1, 2, 4, and 11 are currently amended.

No new matter has been introduced by virtue of the amendments made herein. Accordingly, applicants respectfully request their entry. In view of the amendments made herein and the remarks below, applicants respectfully request reconsideration and withdrawal of the rejection set forth in the October 12, 2005 Office Action.

Claim Objections

The Examiner objected to claim 4 because of the recitation of the term “optionally”. In response, applicants have amended this claim to delete the term.

Rejection under 35 USC § 112, first paragraph

Claims 5-6 and 11-15 were rejected under 35 USC § 112, first paragraph, as lacking enablement for the disorders other than anxiety or depression.

Without prejudice and solely in the interests of facilitating prosecution, applicants have deleted 5-6 and amended claim 11 to delete from said claims the diseases that the Examiner contends are lacking enablement.

Accordingly, Applicants submit that the rejection under 35 USC § 112, first paragraph is moot and respectfully request the withdrawal of the rejection.

Rejection under 35 USC § 112, second paragraph

Claims 1-15 were rejected under 35 USC § 112, second paragraph, as being indefinite.

The Examiner states that claim 1 and the claims dependent upon it are rejected because the phrase “prodrug thereof” is indefinite. Without prejudice and solely in the interests of facilitating prosecution, applicants have amended the claim and removed the term “prodrug thereof”. Accordingly, applicants submit that the rejection under 35 USC § 112, second paragraph is moot and respectfully request the withdrawal of the rejection.

In view of the amendments set forth herein and remarks above, applicants respectfully submit that the pending claims are fully allowable, and solicit the issuance of a notice to such effect. If a telephone interview is deemed to be helpful to expedite the prosecution of the subject application, the Examiner is invited to contact applicants' undersigned attorney at the telephone number provided.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Date: 11/11/00

M. Heller
Michelle Heller
Reg. No. 57,038

Jolene Appleman
Attorney for Applicant(s)
Reg. No. 35,428

Pfizer Inc
Patent Department
150 East 42nd Street – 5th Floor
New York, NY 10017-5755
(212) 733-4827